Applied pharmacology in percutaneous coronary intervention: You can't fight mother nature.

Differential outcomes based on target vessel diameter persist in the era of second generation drug eluting stents. These differences are mainly driven by need for target vessel revascularization without appreciable differences in hard atherosclerotic cardiovascular disease outcomes that is, mortality and myocardial infarction. Future non mechanistic treatment options based on patient characteristics maybe needed.